ImmuCell (ICCC) Q1 2025 earnings summary

Executive summary

• Achieved record product sales of $8.1 million in Q1 2025, up 11% year-over-year, with strong performance from the First Defense® product suite and significant gross margin expansion.

• Net income for Q1 2025 was $1.4 million, reversing a net loss of $438,000 in Q1 2024, driven by higher sales and improved gross margin.

• Production capacity for First Defense® expanded to over $30 million annually, supporting future growth and backlog reduction.

• No contamination events for over a year, reflecting improved operational controls and process improvements.

• Re-Tain® remains in regulatory review, with FDA approval pending; initial market entry will use existing inventory under Investigational Product use.

Financial highlights

• Product sales reached $8.1 million in Q1 2025, up from $7.3 million in Q1 2024; gross margin improved to 42% from 32% year-over-year.

• Adjusted EBITDA for Q1 2025 was $2.3 million, up from $458,000 in Q1 2024; trailing 12-month adjusted EBITDA reached $3.3 million.

• Net income was $1.4 million ($0.16/share) in Q1 2025, compared to a net loss of $0.4 million ($0.06/share) in Q1 2024.

• Cash and cash equivalents increased to $4.6 million as of March 31, 2025, up from $3.8 million at year-end 2024.

• Order backlog reduced from $4.4 million at year-end 2024 to $4 million at Q1-end and further to $3.4 million by May 6, 2025.

Outlook and guidance

• Management expects existing cash and anticipated gross margin to be sufficient for at least the next 12 months.

• Continued focus on expanding product lines, including the launch of a bulk powder format for large ranches later in 2025.

• Expectation of higher EBITDA and revenue in upcoming quarters due to backlog clearance and increased production capacity.

• Cautious on providing specific forward projections, especially for new products like Re-Tain®, due to market and regulatory uncertainties.

• Product development expenses for Re-Tain® are being reduced in 2025, targeting $2.1 million.